# BridgeBio Pharma, Inc. Common Stock (BBIO)

> BridgeBio Pharma, Inc. Common Stock (BBIO) trades at $78.01 (+1.58%) as of 4:09:19 AM EST on Nov 19, 2026, +15.48% over the past month. Market cap is $15.2B, with 7.1 days to cover in short interest.

Canonical: https://massive.com/quote/bbio
Data as of: 2026-11-19T09:09:19.599Z (15-minute delayed)
Source: Massive (https://massive.com/docs/llms.txt)

## Price

**$78.01** +1.21 (+1.58%)
As of 4:09:19 AM EST on Nov 19, 2026 · 15-minute delayed
Nasdaq · usd

## Stock performance

How BridgeBio Pharma, Inc. Common Stock (BBIO) stock has performed from one day to one year, with its 52-week range.

| Period | Return |
| --- | --- |
| 1D | +1.58% |
| 1W | -1.92% |
| 1M | +15.48% |
| YTD | +1.99% |
| 1Y | +20.72% |
| 52-wk range | $62.50 – $93.42 |

From daily closes through Nov 18, 2026.

## Key statistics

Today's trading snapshot for BBIO: day range, open, previous close, volume and market cap.

| Measure | Value |
| --- | --- |
| Day range | $75.99 – $78.25 |
| Open | $76.45 |
| Prev close | $76.80 |
| Volume | 3.65M |
| Market cap | $15.2B |
| Shares out | 194.8M |

## Valuation and profitability ratios

Valuation and profitability ratios for BridgeBio Pharma, Inc. Common Stock: P/E, P/S, P/B, ROE and more.

| Measure | Value |
| --- | --- |
| P/E | — |
| P/S | 16.07 |
| P/B | -9.14 |
| P/FCF | — |
| ROE | 35.6% |
| ROA | -27.4% |
| Debt/Equity | -1.49 |
| Div yield | 0.02% |

As of Nov 18, 2026

## Insider trading

[BridgeBio Pharma, Inc. Common Stock (BBIO) insider trading](https://massive.com/quote/bbio/insider-trading.md): open-market Form 4 buys and sells by BridgeBio Pharma, Inc. Common Stock insiders over the last 12 months.

## 8-K filings

Material corporate events BridgeBio Pharma, Inc. Common Stock has disclosed to the SEC on Form 8-K.

- Oct 29, 2026 · [Quarterly earnings](https://massive.com/quote/sec-filings/8-k/earnings-releases.md)
  “On October 29, 2026, BridgeBio Pharma, Inc. (the "Company") reported recent business updates and its financial results for the third quarter ended September 30, 2026.”
- Oct 13, 2026 · [Regulatory decision](https://massive.com/quote/sec-filings/8-k/regulatory-decisions.md)
  “On October 6, 2026, BridgeBio Pharma, Inc. issued a press release titled "BridgeBio Announces FDA Acceptance and Priority Review of NDA for Oral Infigratinib for Children with Achondroplasia."”
- Aug 17, 2026 · Public offering
  “The Offering was made pursuant to the Company's effective shelf registration statement on Form S-3ASR (File No. 333-297701), including the prospectus dated July 24, 2026, as supplemented by a prospectus supplement dated August 13, 2026, filed on August 14, 2026. The sale of the Shares is expected to be completed on August 17, 2026.”
- Jul 22, 2026 · [Regulatory decision](https://massive.com/quote/sec-filings/8-k/regulatory-decisions.md)
  “BridgeBio Announces FDA Acceptance of NDA for Encaleret for ADH1. On July 22, 2026, BridgeBio Pharma, Inc. issued a press release titled 'BridgeBio Announces FDA Acceptance of NDA for Encaleret for ADH1.'”
- Jul 2, 2026 · Charter amendment
  “In connection with the issuance of the Preferred Stock, on the Closing Date, the Company filed a Certificate of Designations with the Secretary of State of the State of Delaware, establishing the designations, powers, preferences and rights of the Preferred Stock. The Certificate of Designations became effective upon filing.”

## BBIO short interest

How heavily BBIO is shorted: shares short, days to cover and average daily volume.

| Measure | Value |
| --- | --- |
| Days to cover | 7.1 |
| Short interest | 20.85M |
| Avg volume | 2.95M |

As of Oct 30, 2026 · reported to FINRA twice monthly.

## BBIO news

The latest news and headlines about BridgeBio Pharma, Inc. Common Stock (BBIO).

- [Should You Invest $1,000 in BridgeBio Pharma Right Now?](https://www.fool.com/investing/2026/11/02/should-you-invest-1000-in-bridgebio-pharma-now/?source=iedfolrf0000001) · The Motley Fool · Nov 2, 2026 · positive sentiment
- [4 Biotech Stocks With Promising Late-Stage Drug Pipelines to Watch Now](https://www.zacks.com/stock/news/3011299/4-biotech-stocks-with-promising-late-stage-drug-pipelines-to-watch-now?cid=CS-ZC-FT-analyst_blog|investment_ideas-3011299) · Zacks Investment Research · Oct 20, 2026 · positive sentiment
- [Acoramidis Associated with Significantly Improved Clinical Outcomes Versus Tafamidis in ATTR-CM in an Independent, Real-World Study of U.S. Electronic Health Records](https://www.globenewswire.com/news-release/2026/10/11/3378528/0/en/acoramidis-associated-with-significantly-improved-clinical-outcomes-versus-tafamidis-in-attr-cm-in-an-independent-real-world-study-of-u-s-electronic-health-records.html) · GlobeNewswire Inc. · Oct 11, 2026 · positive sentiment
- [Encaleret Increased Bone Turnover and Improved Participant-Reported Symptoms in the Phase 3 CALIBRATE Trial in ADH1](https://www.globenewswire.com/news-release/2026/10/11/3378507/0/en/encaleret-increased-bone-turnover-and-improved-participant-reported-symptoms-in-the-phase-3-calibrate-trial-in-adh1.html) · GlobeNewswire Inc. · Oct 11, 2026 · positive sentiment
- [FDA Grants Priority Review to BridgeBio's Dwarfism Drug Filing](https://www.zacks.com/stock/news/3002048/fda-grants-priority-review-to-bridgebio-s-dwarfism-drug-filing?cid=CS-ZC-FT-analyst_blog|company_news_medical_sector-3002048) · Zacks Investment Research · Oct 7, 2026 · positive sentiment

## About BridgeBio Pharma, Inc. Common Stock

BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. Its key drug is Attruby (acoramidis), an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.

| Measure | Value |
| --- | --- |
| Exchange | Nasdaq |
| Market | stocks |
| Type | CS |
| Currency | USD |
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 839 |
| Listed | Jun 27, 2019 |

[Company website](https://www.bridgebio.com)

## FAQ

### What is the BridgeBio Pharma, Inc. Common Stock (BBIO) stock price today?

BridgeBio Pharma, Inc. Common Stock (BBIO) is trading at $78.01 (+1.58% on the day) as of 4:09:19 AM EST on Nov 19, 2026. Prices are delayed at least 15 minutes; real-time quotes are available from the Massive API.

### What is BridgeBio Pharma, Inc. Common Stock?

BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene…

### What is the short interest in BBIO?

As of Oct 30, 2026, BBIO has 20.85M shares short and 7.1 days to cover.

### What exchange is BBIO listed on?

BridgeBio Pharma, Inc. Common Stock (BBIO) trades on Nasdaq in USD, in the PHARMACEUTICAL PREPARATIONS industry.

## Live data

Prices here are 15-minute delayed. For real-time BBIO quotes and the full history behind this page, use the Massive API or MCP server:

- `GET https://api.massive.com/v3/snapshot?ticker.any_of=BBIO`

Requests need a Massive API key. API reference for agents: https://massive.com/docs/llms.txt. Connect an AI agent through the Massive MCP server: https://massive.com/docs/ai-tools.

## Related

- [BridgeBio Pharma, Inc. Common Stock (BBIO) insider trading](https://massive.com/quote/bbio/insider-trading.md)
- [SEC 8-K events](https://massive.com/quote/sec-filings/8-k.md)
- [Markets overview](https://massive.com/quote/index.md)

Nothing here is investment advice. Data and content are provided for informational purposes under the Massive Terms of Service: https://massive.com/terms
